China Anemia Drugs Market Analysis Report 2022 to 2030

China Anemia Drugs Market Analysis

$ 3999

China's Anemia drugs market was valued at 1.28 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $2.83 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in income and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Roche, Novartis, Sanofi, Shanghai Pharmaceuticals, Sinopharm Group, Jiangsu Hengrui Medicine, and Guangzhou Baiyunshan Pharmaceutical among others.

ID: IN10CNPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Nandini Shah

Buy Now

China Anemia Drugs Market Executive Summary

The China Anemia Drugs market was valued at 1.28 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $2.83 Bn in 2030. Anemia is a condition in which the amount of red blood cells or their capacity to carry oxygen is insufficient to meet physiological needs. Anemia has a negative impact on health and social economic development, with children and women being particularly vulnerable. Anemia can harm cognitive development and physical growth in children from infancy to puberty, and it is linked to higher morbidity. Anemia is still a major public health concern around the world.

In Western China, the median prevalence of anemia in children under the age of five is 43%, which is much higher than the national norm. Qinghai province had the greatest prevalence rates (59.1%-75.74%), with the highest levels reported among children aged 6-24 months.

Market Dynamics

Market Growth Drivers

Anemia is a major public health problem in China, with a prevalence of around 20% in the general population and up to 50% in certain high-risk groups such as pregnant women and young children. With the aging population in China, the incidence of anemia is increasing, which is driving the demand for anemia drugs. China has made significant investments in its healthcare infrastructure, which is increasing access to anemia drugs for those who need them. As income levels are rising in China, the spending on healthcare is also increasing, which is driving the demand for anemia drugs. With this, the Chinese government has been implementing various initiatives to address the prevalence of anemia in the country, which is increasing awareness of the condition and the demand for anemia drugs. China has a strong and growing pharmaceutical industry, which is contributing to the growth of the anemia drugs market.

Market Restraints

There is a shortage of trained healthcare professionals in China, including those who can provide home healthcare services. This can limit the availability and quality of home healthcare services in the country. The rapid increase in nursing demand, along with the gradual increase in the number of qualified nurses, has resulted in a severe shortage of nurses in China. With the fast growth of the older population and babies, this problem will worsen. Because changes in China's demographic structure are inescapable, China's best option is to lower nurses' workload and job pressure while dramatically increasing nurses' pay. The government could take steps to entice more students to work as nurses, so alleviating the looming sad reality. There is a general lack of awareness about home healthcare services in China, which can limit the demand for these services. Also, in China, there is a traditional preference for hospital-based care, which can be a barrier to the adoption of home healthcare services. The collection and sharing of personal health information in-home healthcare can raise privacy concerns, which may limit the adoption of home healthcare services in China.

Competitive Landscape

Key Players

Pfizer
Amgen
Roche
Novartis
Sanofi
Shanghai Pharmaceuticals
Sinopharm Group
Jiangsu Hengrui Medicine
Guangzhou Baiyunshan Pharmaceutical

Recent News

On November 28, 2022, China's National Medical Products Administration (NMPA) approved Ferinject (ferric carboxymaltose), an intravenous iron therapy preparation for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective or cannot be administered. Ferinject has already been approved for sale in 85 countries globally.

Healthcare Policies and Regulatory Landscape

The National Medical Product Administration ("NMPA"), formerly known as the China Food and Drug Administration, is in charge of awarding drug and medical device marketing authorizations and monitoring product quality.

The National Health Commission ("NHC") is in charge of overall healthcare reform direction, as well as administering China's Essential Drugs List ("EDL") and managing drug tendering and procurement procedures.

Reimbursement Scenario

In terms of drug reimbursement, China's medical insurance system was first implemented in 1998 and has since been gradually expanded to include the majority of the Chinese people. Individual members in the national medical insurance scheme, as well as their employers (if any), must contribute to the medical insurance funds by paying a monthly insurance premium. Participants in medical insurance programs are eligible for full or partial payment of the cost of medicines included in the NRDL, which includes over 2,000 Western and Chinese medicines classified as Class A and Class B drugs. Class A pharmaceuticals are typically low-cost and clinically required drugs that can be fully reimbursed, but Class B drugs are frequently higher-priced or novel drugs that need patients to bear 10-40% of the entire cost.

The most recent NRDL, released in 2020, contains a total of 2,800 drug goods, 1,264 of which are Western medications and 1,315 of which are unique Chinese medicines. NHSA negotiation-based pharmaceuticals are 221 drug items that will be supplied at a low agreed-upon price during the length of the related purchasing agreement. Each province may develop its own Provincial Drug Reimbursement List based on the NRDL and subject to specific limits and processes, however, the provincial version of the Reimbursement Drug List is expected to be phased out in the future.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Billion):

Iron Deficiency
CKD (Chronic Kidney Disease)
Sickle Cell
Aplastic
Others

By Drugs

Dietary Supplements
Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacy
Store Pharmacy
Online
Others

The distribution channel for anemia drugs in China is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.